BD Launches Self-Collection HPV Testing to Enhance Global Cervical Cancer Screening Access
- Becton Dickinson has launched a self-collection HPV testing solution to improve cervical cancer screening access globally.
- The BD COR™ System automates sample processing, enhancing laboratory efficiency and reliability of test results.
- BD's innovation aims to reduce cervical cancer incidence and mortality rates through easier and safer screening methods.
BD Expands Access to Cervical Cancer Screening with Innovative Self-Collection HPV Testing Solution
Becton, Dickinson and Company (BD), a leading player in the global medical technology sector, has launched a groundbreaking self-collection solution for HPV testing, targeting markets outside the United States. This innovation enables individuals to collect samples at home, which are then seamlessly processed in laboratories using the advanced BD COR™ System. The introduction of this self-collection method marks a significant advancement in cervical cancer screening, particularly in regions with limited access to traditional healthcare services. The new swab technology, which has received certification under the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe, aims to enhance public health efforts by making cervical cancer screening more accessible.
The design of the self-collection solution prioritizes safety and simplicity. Unlike previous methods that often require liquids or complicated devices, BD's new approach offers a non-invasive option that allows users to mail samples directly from their homes to labs. This ease of use is vital for encouraging widespread participation in cervical cancer screening programs, which are essential for early detection and treatment. Moreover, the BD COR™ System automates the processing of these samples, eliminating the need for manual preparation. This automation not only streamlines laboratory operations but also allows clinical laboratory technologists to redirect their efforts toward more complex and valuable tasks, ultimately leading to enhanced overall efficiency.
Nikos Pavlidis, the worldwide president of BD Diagnostic Solutions, highlights that the certification of this self-collection solution represents a critical step in improving global access to cervical cancer screenings. The innovative workflow incorporates features such as onboard rehydration technology, 30-day dry sample stability, and a straightforward mailing process. As the BD Onclarity™ HPV Self-Collection with Onboard Rehydration Fully Automated Solution approaches its commercial availability in IVDR-recognized markets, it is poised to make a substantial impact on public health initiatives, supporting efforts to reduce cervical cancer incidence and mortality rates around the world.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

